Abbreviations 20 apoA-I, apolipoprotein A-I; 21 CE, cholesteryl esters; 22 ELISA, enzyme-linked immunosorbent assay; 23 FED, fish−eye disease; 24 FLD, classical familial LCAT deficiency; 25 GGE, gel gradient electrophoresis; 26 HDL, high-density lipoproteins; 27 HDL-C, cholesterol in high-density lipoproteins; 28 LCAT, lecithin:cholesterol acyltransferase 29 LDL-C, cholesterol in low-density lipoproteins 30 31 ABSTRACT 32 33 Genetic LCAT deficiency is a rare recessive autosomal disease due to loss-of-function mutations in 34 the gene coding for the enzyme lecithin:cholesterol acyltransferase (LCAT). Homozygous carriers are 35 characterized by corneal opacity, haemolytic anaemia and renal disease, which represent the first cause of 36 morbidity and mortality in these subjects. Diagnostic and prognostic markers capable of early detecting 37 declining kidney function in these subjects are not available, and the specific serum or urine proteomic 38 signature of LCAT deficient carriers has never been assessed. Taking advantage of a proteomic approach, 39 we performed 2-DE analysis of carriers' plasma and identified proteins present at different concentration 40 in samples from homozygous carriers. Our data confirm the well-known alterations in the concentration 41 of circulating apolipoproteins, with a statistically significant decrease of both apoA-I and apoA-II and a 42 statistically significant increase of apoC-III. Furthermore, we observed increased level of alpha-1-43 antitrypsin, zinc-alpha-2-glycoprotein and retinol-binding protein 4, and reduced level of clusterin and 44 haptoglobin. Interestingly, only beta but not alpha subunit of haptoglobin is significant reduced in 45 homozygous subjects. 46 Despite the limited sample size, our findings set the basis for assessing the identified protein in a 47 larger population and for correlating their levels with clinical markers of renal function and anaemia. 48 49 Keywords 50 LCAT deficiency; apolipoproteins; haptoglobin; haemolysis 51 52 53 Significance 54 55
• The plasma proteome of homozygous and heterozygous carriers of LCAT mutations were 76 analysed. 77 • Decreased levels of apolipoproteins vs control subjects could be confirmed. 78 • The next most relevant change observed was a substantial drop in haptoglobin beta chains. 79 • This finding correlates with altered membrane composition and stability, haemolysis and 80 anaemia. 81 • A few proteins, with diverse biological function, were found at increased levels in heterozygotes. Human lecithin:cholesterol acyltransferase (LCAT) is a plasma glycoprotein responsible of the 86 synthesis of most of the plasma cholesteryl esters (CE) in humans. LCAT plays a central role in the 87 intravascular metabolism of high-density lipoprotein (HDL) and in the determination of the levels of 88 cholesterol associated with them (HDL-C) [1] . Mutations in the LCAT gene cause two LCAT deficiency 89 syndromes, classical familial LCAT deficiency (FLD, MIM# 245900) and fish-eye disease (FED, MIM# 90 136120) [2] . The differential diagnosis of FLD and FED is based on stringent biochemical criteria and is 91 restricted to homozygotes or compound heterozygotes for these mutations. FLD cases have a completely 92 defective cholesterol esterification; as a result, there is very little CE in plasma, and unesterified 93 cholesterol accumulates in all plasma lipoprotein fractions. In FED cases, LCAT does not esterify 94 cholesterol in HDL, which represent the preferred substrate of the enzyme, but does it so in VLDL and 95 LDL: as a result, CE are present in plasma if at much reduced levels [2] . 96 Genetic LCAT deficiency is characterized by an abnormal plasma lipoprotein profile featuring a low 97 HDL-C level, with mainly small discoidal pre-beta particles, together with the presence of LpX, an 98 abnormal lipoprotein usually absent in plasma and detectable only in some pathological cases [3, 4] . 99 Carriers also present with corneal opacity due to cholesterol accumulation, mild chronic normochromic 100 anaemia, and renal disease. Renal disease, which ultimately progresses to end-stage renal disease, is the 101 major cause of morbidity and mortality in LCAT-deficient carriers [2] . The dramatic alterations in 102 lipoprotein profile, especially the presence of LpX, have been shown to be directly involved in the 103 glomerulosclerosis development [5] but the cause of kidney failure in these subjects is poorly understood. 104 No specific treatment for renal disease in LCAT deficiency is currently available, and carriers are 105 usually treated symptomatically. The therapy of LCAT deficiency nephropathy mainly aims at delaying 106 the evolution of chronic nephropathy on the basis of available therapies, such as changes in life style and 107 diet and control of complications such as hypertension and proteinuria [2] . FLD patients are often treated 108 by dialysis [6, 7] ; they are candidates for renal transplantation, but the disease can rapidly reoccur in the 109 transplanted tissues within a few years [8] . 110 Not all carriers of LCAT mutations develop renal disease, and the rate of progression of renal disease 111 is unpredictable, even within the same family; some patients rapidly worsen from a mild proteinuria to a 112 rapid deterioration of their renal function [9] . Thus, there is the urgent need for specific diagnostic and 113 prognostic markers, other than traditional measures of renal function, capable of detecting declining 114 kidney function early in time in these individuals in order to address high-risk carriers toward preventive 115 programs and potential therapies. 116 In this context, proteomic provides useful information for the identification and characterization of 117 alterations in plasma protein levels. Up to now no specific serum or urine proteomic signature of LCAT 118 deficient carriers has been defined. In this work, we applied a proteomic approach to investigate the 119 plasma pattern in homozygous and heterozygous carriers of LCAT deficiency, in comparison with the 120 pattern of non-affected subjects. 17.5% polyacrylamide gradients on 160x140 mm 2 SDS slabs using the discontinuous buffer system of 156 Laemmli [15] . Finally, the proteins were stained with 0.3% (wt/vol) Coomassie.
was statistically different among the three groups of subjects, was made as previously described [16] . 160 
161
For haptoglobin phenotyping, equal volumes of human plasma were diluted in sample loading buffer 162 (1:100) and analysed as previously described [17] . 163 Briefly, levels of haptoglobin subunits were evaluated in plasma diluted in sample loading buffer 164 (1:100) (20 g/l sodium dodecyl sulfate, 100 ml/l glycerol, 25 mmol/l Tris [pH 6.8], 0.05 g/l bromophenol 165 blue, 50 mmol/l dithiothreitol), and loaded on a 18% T polyacrylamide gel with Hp standards 1-1 and 2-2 166 (Sigma-Aldrich, Milan, Italy). 167 Immunoblotting was performed with a 1:10,000 dilution of polyclonal rabbit anti-human Hp (Sigma- The proteins differing in volume in one or more spots, corresponding to one or more of their PTM-201 species or of their proteolytic fragments, in a patients vs controls comparison, are outlined in the top 202 panel; their numbering corresponds to that of the entries in Table 2 and in Supplementary Table 1, which   203 contain the identifications made possible by MS analysis of the picked spots. Table 2 summarizes 
220
In order to find a rationale for the above discrepancy, we investigated by immunoblotting after 1-DE 221 the abundance of the haptoglobin subunits (alpha and beta), characterized by different molecular weights. 222 With this approach, we observed that homozygous subjects are characterized by a significant reduction of 223 the beta subunit (homozygotes, 0.99 ± 0.38 AU; heterozygotes, 1.43 ± 0.14 AU; controls 1.44 ± 0.22 AU; 224 P for trend = 0.016; Figure 2 ) but not of the alpha subunit. 
